The Serum Institute of India has been at the center of vaccine production for COVID-19. But as the second wave crashes down on the country, an export ban via the Indian central government has put the company in a tough spot, with CEO Adar Poonawalla even fleeing to London. SII is at a point where it no longer holds the promise of production monopoly, and must expand to newer geographies and technology to strengthen its position as a global biotech company. Story originally reported by Seema Singh. News clips sourced from NDTV. Music and editing by Sameer Rahat from Baqsa Studios. Psst share your feedback with us on [email protected]